Companies · Biotechnology

Nexgel, Inc.

LANGHORNE · Biotechnology

Diligence memoA one-page analyst read on Nexgel, Inc. — recommendation, valuation, rhythm, risks.
$4.6M
Total raised · real
6
Rounds
1.1×
Latest step-up
Top 59%
Sector rank · raised
Seed
Latest stage · inferred · Thu Sep 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Nexgel, Inc. looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.59× the median modeled value of Seed Biotechnology companies in 2019–2021 (186 peers) — value vs value, same stage and era.
Dormant
  • Last raise 4.8 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Nexgel, Inc. is one of 4291 Biotechnology companies tracked from LANGHORNE. By capital raised it ranks mid-pack (ahead of 42% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
20
Investors (latest)
2021-09-02
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$13M$25M$38M$50MPre-Seed · 2009-08-26 Raised $416K (real) Modeled valuation $23M (est)$416K$23MPre-Seed2009Pre-Seed · 2019-09-10 Raised $175K (real) Modeled valuation $9.7M (est)$175K$9.7MPre-Seed2019Pre-Seed · 2020-07-30 Raised $395K (real) Modeled valuation $21M (est)$395K$21MPre-Seed2020Pre-Seed · 2020-11-25 Raised $515K (real) Modeled valuation $22M (est)$515K$22MPre-Seed2020Seed · 2021-03-11 Raised $1.5M (real) Modeled valuation $45M (est)$1.5M$45MSeed2021Seed · 2021-09-02 Raised $1.6M (real) Modeled valuation $38M (est)$1.6M$38MSeed2021+$175K+$395K+$515K+$1.5M+$1.6MCumulative $4.6M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$416K · 2009
Pre-Seed extension$175K · 2019
Pre-Seed extension$395K · 2020
Pre-Seed extension$515K · 2020
Seed$1.5M · 2021
Seed extension$1.6M · 2021

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$37.6M
Base estimate est.
$1.2M
Conservative case
$214.6M
Upside case
$8.1M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $22.9M · 2009-08-262009Pre-Seed · modeled $9.7M · 2019-09-10Pre-Seed · modeled $20.7M · 2020-07-30Pre-Seed · modeled $22.1M · 2020-11-25Seed · modeled $45.3M · 2021-03-11Seed · modeled $37.6M · 2021-09-022021
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
32%
Survival probability
14% low · 50% high
1.74×/yr
Annual markup
2.28×/yr upside case
4.8 yr
Elapsed time used
4.8 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
29 mo
Avg between rounds
$384K/yr
Capital velocity
16.8 yr
On record since
2009
First round
6
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.6× of median
This company$4.6M
Sector median$7.2M
Latest round — vs other Seed rounds in sector (real $, this stage) 0.9× of median
This company$1.6M
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 0.6× of median
This company$37.6M
Sector median$64.2M

Raised more than 42% of sector peers (real $). Modeled value above 39% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #142 of 186.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0MCapital raised (log)Entac Medical, Inc. · Seed Raised $4.0M · modeled $177.6M (est)Novo Biosciences, Inc. · Seed Raised $4.0M · modeled $177.6M (est)Korro Bio, Inc. · Seed Raised $4.0M · modeled $177.6M (est)ReGelTec, Inc. · Seed Raised $6.0M · modeled $177.6M (est)TamuroBio Inc. · Seed Raised $4.0M · modeled $177.6M (est)Initial Therapeutics, Inc. · Seed Raised $3.8M · modeled $168.3M (est)Helaina Inc · Seed Raised $4.4M · modeled $164.8M (est)Onchilles Pharma, Inc. · Seed Raised $3.6M · modeled $158.5M (est)UVision 360, Inc. · Seed Raised $4.6M · modeled $155.7M (est)Safeguard Biosystems Holdings Ltd · Seed Raised $3.5M · modeled $155.4M (est)Enable Medicine Inc. · Seed Raised $3.6M · modeled $152.1M (est)Newomics Inc. · Seed Raised $3.9M · modeled $148.7M (est)Nexgel, Inc. (this company) Raised $4.6M · modeled $37.6M (est)Nexgel, Inc.
CompanyStageRaised · realValue · estvs peer med.
Entac Medical, Inc.Seed$4.0M$177.6M2.77×
Novo Biosciences, Inc.Seed$4.0M$177.6M2.77×
Korro Bio, Inc.Seed$4.0M$177.6M2.77×
ReGelTec, Inc.Seed$6.0M$177.6M2.77×
TamuroBio Inc.Seed$4.0M$177.6M2.77×
Initial Therapeutics, Inc.Seed$3.8M$168.3M2.62×
Helaina IncSeed$4.4M$164.8M2.57×
Onchilles Pharma, Inc.Seed$3.6M$158.5M2.47×
UVision 360, Inc.Seed$4.6M$155.7M2.43×
Safeguard Biosystems Holdings LtdSeed$3.5M$155.4M2.42×
Enable Medicine Inc.Seed$3.6M$152.1M2.37×
Newomics Inc.Seed$3.9M$148.7M2.32×
Nexgel, Inc. this companySeed$4.6M$37.6M0.59×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$416K2009-08-26$2.3M$22.9M85%
Pre-Seed$175K2019-09-10$972K$9.7M90%
Pre-Seed$395K2020-07-30$2.2M$20.7M90%
Pre-Seed$515K2020-11-25$2.9M$22.1M90%
Seed$1.5M2021-03-11$7.5M$45.3M90%
Seed$1.6M2021-09-02$8.1M$37.6M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$416K2009-08-26
    • First recorded raise — entered as Pre-Seed.
    • 6 investors on this round.
  2. Pre-Seed$175K2019-09-10
    • Raised again after 120 mo — slower than the ~14 mo sector norm.
    • Round 2.4× smaller than the prior — bridge or down round.
    • Switched to Rule 506(b) (was Rule 06).
    • 2 investors on this round.
  3. Pre-Seed$395K2020-07-30
    • Raised 11 mo later, in step with the ~14 mo sector norm.
    • Round 2.3× larger than the prior — scaling up.
    • 5 investors on this round.
  4. Pre-Seed$515K2020-11-25
    • Came back fast: 4 mo vs the ~14 mo sector norm.
    • Round 1.3× larger than the prior — scaling up.
    • 12 investors on this round.
  5. Seed$1.5M2021-03-11
    • Came back fast: 3 mo vs the ~14 mo sector norm.
    • Round 2.9× larger than the prior — scaling up.
    • 1 investor on this round.
  6. Seed$1.6M2021-09-02
    • Came back fast: 6 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 20 investors on this round.
Intelligence
2024 ~Q1
Modeled next raise · ~29mo cadence
$1.7M
Modeled next size est.range $1.6M$2.8M
1.1×
Last step-up
$384K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Jerome Zeldis5 other2020-07
Richard Rosenblum5 other2009-08
Adam Levy2 other2020-07
David Stefansky2 other2020-07
Benjamin Mayer1 other2009-08
Adam J Drapczuk2021-09
Adam R. Levy2019-09
David R. Stefansky2019-09
Joe R. Williams2019-09
Michael W Chorske2009-08
Miranda J Toledano2021-09
Nachum R. Stein2019-09
Nachum Stein2020-07
Steven Mark Glassman2020-11
Yaakov J Spinrad2021-09
Registry & provenance

Nexgel, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1468929
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Alliqua BioMedical, Inc.BiotechnologySeries A$52.6M$100.1Mnetwork3 shared operators · same sector
Serpex Medical Inc.BiotechnologySeed$4.6M$40.3Msame sector · same stage
AvidBiotics Corp.BiotechnologySeed$4.8M$37.9Msame sector · same stage
Peytant Solutions, Inc.BiotechnologySeed$4.9M$30.4Msame sector · same stage
NeurAxon(USA), Inc.BiotechnologySeed$4.4M$34.7Msame sector · same stage
BioHSV Holdings, Inc.BiotechnologySeed$5.0M$33.5Msame sector · same stage
Protein Forest, Inc.BiotechnologySeed$5.0M$33.3Msame sector · same stage
Maxcyte, Inc.BiotechnologySeed$5.1M$33.8Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Nexgenia Inc.BiotechnologySeed$5.3M92%
Nexeon Medsystems IncBiotechnologySeries B$46.2M91%
NERx Biosciences, Inc.BiotechnologyPre-Seed$4.8M91%
Nexsis Biosciences LLCBiotechnologyPre-Seed$16.0M91%
Nexgen Forensic Sciences, Inc.BiotechnologyPre-Seed$24.9M90%
NX Pharmagen Inc.BiotechnologySeed$7.4M90%
Nexo Therapeutics, Inc.BiotechnologySeries C$993.8M89%
NeuroX Innovations Inc.BiotechnologyPre-Seed$11.9M89%
Frequently asked
How much funding has Nexgel, Inc. raised?
Nexgel, Inc. has raised approximately $4.6M in disclosed capital across 6 recorded financing rounds, aggregated from public filings.
What is Nexgel, Inc.'s estimated valuation?
Provath's modeled valuation for Nexgel, Inc. is approximately $37.6M (modeled range $1.2M–$214.6M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Nexgel, Inc. at?
Nexgel, Inc.'s latest modeled financing stage is Seed. Its most recent recorded round closed around Thu Sep 02.
What does Nexgel, Inc. do and where is it based?
Nexgel, Inc. operates in the Biotechnology sector, based in LANGHORNE.
Explore related

See where Nexgel, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Nexgel, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.